American Home Products Corporation

Wyeth

Other

John Wyeth Brother, Limited

James Albert Nelson

Uresh Shantilal Shah

Richard Eric Mewshaw

Annmarie Louise Sabb

John H Musser

Anthony F Kreft, Iii

Gregory Scott Welmaker

Amedeo A Failli

Michael Sotirios Malamas

Sharon J Rosenzweig-Lipson

Robert Lewis Vogel

Annette L Banker

Mira A Kanzelberger

Christopher A Demerson

Dennis Michael Kubrak

Joan E Sabalski

Gary Paul Stack

Terence J Ward

Ian A Cliffe

Panolil C Raveendranath

Reinhardt Bernhard Baudy

Sreenivasulu Megati

Madelene M Antane

Reinhold H Bender

Howard L Mansell

Michael D Smith

This invention provides compounds of the formulae: wherein:

Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives

This invention provides compounds of formula I, wherein

2,3,4,4a-tetrahydro-1H-pyrazino(1,2-a) quinoxalin-5(6H)one derivatives

Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diaza-cyclopenta&lsqb;a&rsqb;naphthalene

Processes for preparation of cyclopenta&lsqb;b&rsqb;&lsqb;1,4&rsqb;diazepino&lsqb;6,7,1-hi&rsqb;indoles and derivatives

Cyclopenta&lsqb;b&rsqb;&lsqb;1,4&rsqb;diazepino&lsqb;6,7,1-hi&rsqb;indoles and derivatives

2,3,4,4a-tetrahydro-1H-pyrazino&lsqb;1,2-a&rsqb;quinoxalin-5(6H)one derivatives

2,3,4,4A-tetrahydro-1H-pyrazino&lsqb;1,2-A&rsqb;quinoxalin-5(6H)one derivatives

Compounds having dopaminegic activity are provided, having the formula:

4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists

Compounds effective in treating disorders of the serotonin-affected neurological systems are provided, such compounds having the following formula: ##STR1## wherein: R.sub.1 is hydrogen, lower alkyl, phenyl, or substituted phenyl;

N-aryloxyethyl-indoly-alkylamines for the treatment of depression

This invention relates to D.sub.2 dopaminergic compounds of the formula ##STR1## wherein: R.sup.1 is hydrogen, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, straight-chain or branched alkyl group having up to 6 carbons or benzyl optionally substituted by one to three substituents selected from halogen, amino, nitro, hydroxy, and C.sub.1 -C.sub.6 alkoxy;

4-aminoalkoxy-1H-benzoimidazoles

Disclosed are compounds of the formula ##STR1## wherein: R.sup.1 is hydrogen or C.sub.1 -C.sub.6 alkyl;

4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one dopamine autoreceptor

This invention relates to a novel series of compounds having potency at the dopamine D.sub.2 receptor which are illustrated by the following Formula I: ##STR1## wherein: R.sup.1 is hydrogen or C.sub.1 -C.sub.6 alkyl;

4-aminoalkoxy-1,3-dihydro-benzoimidazol-2-thiones

This invention relates to compounds of Formula I ##STR1## wherein: R.sup.1 and R.sup.2 are independently selected from hydrogen, straight-chain and branched alkyl group having up to 10 carbon atoms or --(CH.sub.2).sub.m Ar where Ar is phenyl, naphthyl or thienyl, each optionally substituted by one or two substituents selected independently from C.sub.1 -C.sub.6 alkyl, halogen, C.sub.1 -C.sub.6 alkoxide and trifluoromethyl;

5-aminoalkoxy-1, 4-dihydroquinoxaline-2, 3-diones

Growing community of inventors

Washington Crossing, PA, United States of America

James Albert Nelson